Aptevo jumps after blood cancer therapy shows 100% remission in trial

** Shares of drug developer Aptevo Therapeutics APVO.O rise 55% to $2.24

** Co says its experimental blood cancer therapy, mipletamig, led to 100% remission in an early-to-mid stage trial

** The therapy, tested with venetoclax and azacitidine, is aimed at newly diagnosed acute myeloid leukemia patients who are too frail for intensive chemotherapy

** About 40% of patients had no trace of cancer left in their blood, a sign the disease may be less likely to return - Aptevo

** Mipletamig is a bispecific antibody that targets CD123, a protein found on leukemia cells and helps the immune system kill the cancer without triggering strong immune reactions

** Including session move, stock down 97% YTD